2024
A prospective cohort study on stereotactic radiotherapy in the management of dural recurrence of olfactory neuroblastoma
Goodman C, DeMonte F, Nguyen T, Garden A, Wang C, Wang X, Diao K, Lee A, Reddy J, Moreno A, Spiotto M, Fuller C, Rosenthal D, Ferrarotto R, Raza S, Su S, Warner A, Hanna E, Phan J. A prospective cohort study on stereotactic radiotherapy in the management of dural recurrence of olfactory neuroblastoma. Head & Neck 2024 PMID: 39073252, DOI: 10.1002/hed.27887.Peer-Reviewed Original ResearchStereotactic body radiotherapyOlfactory neuroblastomaOutcomes of stereotactic body radiotherapyTreated with stereotactic body radiotherapyTwo-year local controlHigher local control rateONB patientsPatient-reported quality of lifeLocal control rateProspective cohort studyPatient-reported qualityBrain radionecrosisStereotactic radiotherapyMedian doseTumor controlDural lesionsProspective registryRadiographic progressionControl rateMinimal toxicityCohort studyLocal controlQuality of lifePatientsRecurrenceClinical acceptability of automatically generated lymph node levels and structures of deglutition and mastication for head and neck radiation therapy
Maroongroge S, Mohamed A, Nguyen C, De la Vega J, Frank S, Garden A, Gunn B, Lee A, Mayo L, Moreno A, Morrison W, Phan J, Spiotto M, Court L, Fuller C, Rosenthal D, Netherton T. Clinical acceptability of automatically generated lymph node levels and structures of deglutition and mastication for head and neck radiation therapy. Physics And Imaging In Radiation Oncology 2024, 29: 100540. PMID: 38356692, PMCID: PMC10864833, DOI: 10.1016/j.phro.2024.100540.Peer-Reviewed Original ResearchLymph node levelsAI contoursClinical acceptanceSwallowing structuresComputed tomographyHead and neck radiotherapy patientsHead and neckMedian Dice similarity coefficientLevels I-VDice similarity coefficientRadiotherapy patientsCT scanManual contouringLymphComplex anatomyCT imagesCohortI-VPatientsChewingSimilarity coefficientAnatomyRadiotherapyHeadNode level
2021
Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck
Ferrarotto R, Amit M, Nagarajan P, Rubin M, Yuan Y, Bell D, El-Naggar A, Johnson J, Morrison W, Rosenthal D, Glisson B, Johnson F, Lu C, Mott F, Esmaeli B, Diaz E, Gidley P, Goepfert R, Lewis C, Weber R, Wargo J, Basu S, Duan F, Yadav S, Sharma P, Allison J, Myers J, Gross N. Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. Clinical Cancer Research 2021, 27: 4557-4565. PMID: 34187851, PMCID: PMC8711237, DOI: 10.1158/1078-0432.ccr-21-0585.Peer-Reviewed Original ResearchConceptsCutaneous squamous cell carcinomaInflamed tumor microenvironmentSquamous cell carcinomaHead and neckCSCC-HNNeoadjuvant immunotherapyCell carcinomaTumor microenvironmentPathological responsePD-1 inhibitionCurative-intent surgeryPathological response rateBiomarkers of responseT cell clustersOS ratesNeoadjuvant treatmentPartial responseRecurrent diseaseExploratory endpointsPrimary endpointSecondary endpointsImmune biomarkersFollow-upCyTOF analysisPatients